Rep. Clyburn among speakers at “Research in Your Backyard” press conference

The Medical University of South Carolina (MUSC) this morning hosted “Research in Your Backyard,” a press conference announcing the key findings of a new report from the Pharmaceutical Research and Manufacturers of America (PhRMA) that focuses on clinical trials being conducted by biopharmaceutical research companies and local research collaborators throughout South Carolina. Rep. James Clyburn was a featured speaker at the conference, which took place inside the Drug Discovery Building of the James E. Clyburn Research Center.

Clinical Trials are an Essential Option for Patients

08.26.13 | By

I recently learned of the International Cancer Advocacy Network which provides personalized assistance to patients facing stage IV cancer.  I invited Marcia Horn, President and CEO of ICAN, to elaborate on the mission and programs the organization offers.

Heightened Sense of Urgency to Come to an Agreement

08.26.13 | By

With the Asia-Pacific Economic Cooperation (APEC) leaders meeting scheduled for October and participating countries emphasizing their desire to complete Trans-Pacific Partnership (TPP) negotiations this year, there is a heightened sense of urgency to come to an agreement. This point was reinforced by the start of the 19th round of negotiations in Brunei – just one month after the previous round concluded in Malaysia.

National Psoriasis Foundation Invites You to be a Citizen Pscientist

08.21.13 | By

Many patients are welcoming efforts by biopharmaceutical companies, patient organizations and scientists in academia to actively engage patients in clinical trials and other research opportunities.  It can be empowering to learn more about yourself and your disease, and to know that your participation may even help future patients.

Mental Health and the Biopharmaceutical Pipeline

08.20.13 | By

The New York Times today  put a spotlight on mental health, mistakenly pointing out that we are facing a crisis in innovation for medicines that can help patients suffering from debilitating psychiatric diseases.

Conversations: Clinical Trial Data, Transparency and Patient Privacy

08.20.13 | By

Bringing a medicine to patients, from discovery through FDA review, is a lengthy, costly and sometimes unpredictable process. On average, it takes 10-15 years and an investment of more than $1 billion. As noted previously on the Catalyst, only one out of 5,000-10,000 potential new medicines make it through the multiple and rigorous pre-clinical and clinical trials phases and is ultimately approved by the FDA for patient use.

Public-Private Partnerships and Neurological Diseases

08.16.13 | By

Despite the great medical advances of the last century, there is still a lot of work to be done when it comes to developing medications and treatments to deal with neurological disorders such as Parkinson’s disease. These conditions pose vexing challenges for researchers trying to unlock the secrets that will improve the lives of millions living with the daily challenges that neurological diseases pose.

Bringing Science to Life for Patients

08.15.13 | By

As I read the Wall Street Journal’s article this week on gene breakthroughs in cancer treatment, I felt a range of emotions. First was excitement. Decades of devotion to research have taken science to new heights and it’s important that people are aware of the tremendous progress that has been made. This awareness is what saved the life of Kellie Carey featured in the story.

Sustained Innovation Generated by the Biopharmaceutical Research Sector

08.09.13 | By

In case you missed it, a blog post and article published in Health Affairs by FDA officials earlier this week highlights 25 years of steady and sustained innovation generated by the biopha

Impact of Personalized Medicine on Patients

08.06.13 | By

Last week, I highlighted a Hill briefing hosted by the Personalized Medicine Coalition and the great examples it provided of the impact of personalized medicine on patients. I was reminded why we must advocate for policies that support continued progress against disease and fulfill the promise of personalized medicine.

Pages

Subscribe to RSS - Opinion